AgroAmerica Presents Its 2022 Sustainability Report: A Future Built to Last
18.7.2023 17:12:00 EEST | Business Wire | Press release
AgroAmerica presented its ninth Sustainability Report. This report provides an updated overview of the performance of the company’s banana division and the achievements made in 2022 through its Corporate Sustainability Strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717281841/en/
AgroAmerica's sustainability report details the structure, governance, strategy, and management of the company, with a specific focus on the material issues identified. Over the past year, AgroAmerica has worked on environmental, social, and governance topics that are relevant to the business. (Photo: Business Wire)
"We are pleased to announce that the year 2022 marks the final chapter of our current strategy, as well as the starting point of a significant transformation. In this process, our strong foundation in sustainability will drive a new robust integrated strategy that will shape our path in 2023-24. This exciting step will lead us to continuous improvement and a more sustainable future," explained Fernando Bolaños, CEO of AgroAmerica.
Using a regenerative approach, the company undertakes actions aimed at promoting soil health, resource conservation, biodiversity preservation, and the reduction of carbon emissions. As part of this strategy, AgroAmerica has initiated a project, unique in the region, that protects bees and other pollinators in forest conservation areas located in our operations.
Some of the highlighted achievements included in this report:
- The installation of a macro sanctuary to house and protect more than 30,000 native bees and pollinators.
- Receiving the "2022 Conservation Leadership Award" from the RSPO Excellence Awards to the Mayan Biosphere conservation project.
- Receiving the "Grand Prize in Business Sustainability" from the American Chamber of Commerce for our "Mangrove Ecosystem Restoration Project" on the Pacific Coast of Guatemala.
- Obtaining the “RSPO certification” in our operations in Panama, meaning that all the operations of the tropical oil division in AgroAmerica are now certified.
- The generation of over 12,000 direct and indirect jobs that promote gender equality and development opportunities for our employees, their families and our neighboring communities.
- Contributing to 11 of the United Nations’ Sustainable Development Goals.
- Holding 11 international certifications related to good practices, sustainable operations, and food quality and safety.
- The conservation of more than 970 hectares of forests in areas within our company’s operations.
"We are a world-class corporation that adapts to global market challenges to exceed environmental, governance and social expectations and offer high-value-added products to the world," stated Javier Aguirre, Corporate Director.
This report shows our path forward with a renewed focus on sustainability, and reaffirms our company's commitment to the environment, society, and governance in the production of high-quality sustainable food.
See full report here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230717281841/en/
Contact information
Susana Perez
Communications and Public Relations Coordinator
sperez@agroamerica.com
(+502) 5554-8774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
